
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Appoints Belén Garijo as Chief Executive Officer
2
Former AstraZeneca Executive Charged with Several Offenses in China
3
Today’s China Crucible: What It Means for Pharma
4
FDA Approves Keytruda-Based Regimen for PD-L1–Positive Platinum-Resistant Ovarian Cancer
5




